Trial Profile
A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of GS-9876 in Subjects with Impaired Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Lanraplenib (Primary)
- Indications Cutaneous lupus erythematosus; Lupus nephritis; Rheumatoid arthritis; Sjogren's syndrome
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 16 Mar 2019 Results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 06 Nov 2018 Status changed from recruiting to completed.
- 03 Apr 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.